Analysis

Analysis

Repligen borrows at a quarter of a per cent, and pays elsewhere

Repligen issued $1B of 0.25% convertible notes at a 20% premium and swapped out its 2028 notes, terms cheaper than recent deals by Halozyme and Jazz.

RGEN

Investor Chat

Scorecard

RGEN
Investment Attractiveness: 6.1/10, Above peersThe company’s relative investment appeal, based on financial strength, valuation and execution. · Relative financial and execution position; not a forecast of stock returns. · As of 2026-11-04
Above peers
Company Deal Record: 5/10, Mixed recordHow favorable the company’s past financings have been, with more weight on recent deals. · As of 2026-11-04
Mixed record
Investor Impact: 3/10, LimitedHow important this specific story was to investors when we published it, whether the news was good or bad. · Moderate evidence · As of 2026-11-01
LimitedModerate evidence

Analysis: opinion, not investment advice

Few companies can borrow $1bn at 0.25%. Repligen (RGEN), which sells filtration and chromatography kit to drug makers, did so on October 29th. It agreed to issue $1.0bn of 0.25% convertible senior notes due 2031 in privately negotiated deals, refinancing most of its 2028 notes and raising fresh cash. Our news desk reported the transaction. The coupon is the headline. The cost sits in the conversion premium, the exchange ratio and the buyback bolted on to the side.

The terms

According to the 8-K, about $541.4m of the new notes will be issued in exchange for about $456.8m of Repligen's 1.00% notes due 2028, and about $458.6m will be sold for cash. The initial conversion rate is 4.4176 shares per $1,000, a conversion price of about $226.37, which is a 20.0% premium to the $188.64 last sale on October 29th. Repligen can call the notes from November 6th 2029 if the stock trades at 130% or more of the conversion price. At most 5,301,100 shares can be issued on conversion.

Two side trades matter. Repligen will spend about $120.0m of the cash proceeds buying back its own shares from some of the note buyers at $188.64. And it has been told that the placement agent, which the press release names as J. Wood Capital Advisors, intends to buy about $30.0m of stock from participants at a discount to that price. The company's own filing warns that these purchases could raise the share price, or soften a fall, around the deal.

The business behind it

The borrower is in decent shape. Repligen reported third-quarter revenue of $209m, up 11% on a year earlier, raised its full-year guidance to $844m to $852m, and closed its acquisition of BioLife Solutions in October. The fresh cash is earmarked for working capital and general purposes, including possible acquisitions.

How the terms compare

Two life-science converts from the past three months give a benchmark. Halozyme Therapeutics (HALO) priced $1.3bn of 1.50% notes due 2033 on September 17th at a conversion premium of about 27.5%, and bought capped calls to limit dilution. Jazz Pharmaceuticals (JAZZ) priced $1.1bn of 1.875% exchangeable notes due 2032 on August 27th at a premium of about 42.5%, alongside a $225m share buyback.

Repligen's coupon is the lowest of the three by a distance. Its premium is also the lowest. Convertible investors trade one for the other: they accept less interest in exchange for a cheaper option on the shares. A 20% premium means the notes start converting into equity after a smaller rise in the stock than Halozyme's or Jazz's. Repligen also did not disclose a capped call, so the dilution protection Halozyme bought is absent here. Both choices favour note buyers over existing shareholders at the margin.

The exchange ratio

The swap of old notes for new deserves a closer look. Holders gave up about $456.8m of 2028 notes and received about $541.4m of 2031 notes, roughly 1.19 dollars of new principal for each dollar of old, by our arithmetic. The 2028 notes have an initial conversion price of $203.06, above the $188.64 share price on pricing day, so their conversion option was not in the money at that price. The filings say the exchange amount was "determined as set forth" in the private agreements but do not publish the formula. Some of the uplift may reflect the market value of the old notes, accrued interest or the option's time value; we could not verify which.

The criticism

The people accountable are chief executive and chief financial officer Jason Garland, who sign the company's 10-Q, and a board chaired by Martin Madaus since March 13th 2026. Their deal is cheap on its face and complex underneath. Three questions are fair.

First, why give exchanging holders about $84.6m more principal than they surrendered, and how was that number set? Second, why spend $120m of new borrowing buying stock back from the same investors who bought the notes? The 8-K says the buyback is meant "to facilitate the Transactions" and warns that it and the placement agent's purchases "could increase (or reduce the size of any decrease in)" the market price of the stock or the notes. In our view, that means company cash supports the share price while the notes are priced, a cost that falls on shareholders and that the filing does not quantify. Third, the investors and their allocations are not disclosed. For a private placement that is normal. For a transaction that pairs debt, an exchange and a stock buyback, it leaves shareholders unable to judge who gained most.

These structures are standard in private convertible exchanges, and the filings point to nothing improper. A low coupon still leaves real costs elsewhere in the deal.

What to watch

The closing 8-K and indenture, which should confirm the final amounts; the next 10-Q, which should show the share count after the buyback; and how much of the 2028 notes is left outstanding. If Repligen's acquisitions pay off, a 20% premium will look generous to note buyers. If they do not, the low coupon will look like the right call.


Sources: 8-K and exhibits 99.1 and 99.2 filed October 30th 2026, Q3 release, Q3 10-Q, 2026 proxy, Halozyme and Jazz pricing releases, all linked above. Auditor: Ernst & Young LLP, per the 2026 proxy.

Sources

Every figure comes from the documents above. Chart values come from the company's financial statements as tagged in its SEC filings; derived values are labelled. If you find an error, tell us.

Disclosures

  1. Every figure carries the as-of date of its source.
  2. This analysis was drafted with AI tools from the company's own filings, FDA documents and trial registries. Every number is checked against its source and an editor reviews the piece before it is published.
  3. Our method and conflicts policy: aibio.space/disclosures/

As of , aibio.space has received no compensation from, and has no paid relationship with, the company covered.

Investor Chat

Loading posts…

Settings

Text size
Motion

Stops the moving share lists on the front page.

Your choices are saved in this browser only.

Free membership

Get aibio.space by email, free

Get updates from aibio.space by email. Sign up with your email address to receive updates and offers. Unsubscribe in one click.

No card, no password. With email, we send one message to confirm your address first. With Google or Facebook we receive only your email address.